Pharmacokinetics and In Vitro Blood-Brain Barrier Screening of the Plant-Derived Alkaloid Tryptanthrin^[*]

Abstract

The indolo[2,1-b]quinazoline alkaloid tryptanthrin was previously identified as a potent anti-inflammatory compound with a unique pharmacological profile. It is a potent inhibitor of cyclooxygenase-2, 5-lipooxygenase-catalyzed leukotriene synthesis, and nitric oxide production catalyzed by the inducible nitric oxide synthase. To characterize the pharmacokinetic properties of tryptanthrin, we performed a pilot in vivo study in male Sprague-Dawley rats (2 mg/kg bw i. v.). Moreover, the ability of tryptanthrin to cross the blood-brain barrier was evaluated in three in vitro human and animal blood-brain barrier models. Bioanalytical UPLC-MS/MS methods used were validated according to current international guidelines. A half-life of 40.63 ± 6.66 min and a clearance of 1.00 ± 0.36 L/h/kg were found in the in vivo pharmacokinetic study. In vitro data obtained with the two primary animal blood-brain barrier models showed a good correlation with an immortalized human monoculture blood-brain barrier model (hBMEC cell line), and were indicative of a high blood-brain barrier permeation potential of tryptanthrin. These findings were corroborated by the in silico prediction of blood-brain barrier penetration. P-glycoprotein interaction of tryptanthrin was assessed by calculation of the efflux ratio in bidirectional permeability assays. An efflux ratio below 2 indicated that tryptanthrin is not subjected to active efflux.

Key words

tryptanthrin - UPLC-MS/MS - validation - pharmacokinetics (PK) - blood-brain barrier (BBB)

^* Dedicated to Prof. Dr. Dr. h. c. mult. Kurt Hostettmann in recognition of his outstanding contribution to natural product research.

• References

• 1 Danz H, Stoyanova S, Thomet OAR, Simon HU, Dannhardt G, Ulbrich H, Hamburger M. Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med 2002; 68: 875-880
• 2 Pergola C, Jazzar B, Rossi A, Northoff H, Hamburger M, Sautebin L, Werz O. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo . Br J Pharmacol 2012; 165: 765-776
• 3 Recio MC, Cerdá-Nicolás M, Hamburger M, Ríos L. Anti-arthritic activity of a lipophilic woad (Isatis tinctoria) extract. Planta Med 2006; 72: 715-720
• 4 Recio MC, Cerdá-Nicolás M, Potterat O, Hamburger M, Ríos L. Anti-inflammatory and antiallergic activity in vivo of lipophilic Isatis tinctoria extracts and tryptanthrin. Planta Med 2006; 72: 539-546
• 5 Danz H, Stoyanova S, Wippich P, Brattström A, Hamburger M. Identification and isolation of the cyclooxygenase-2 inhibitory principle in Isatis tinctoria . Planta Med 2001; 67: 411-416
• 6 Ishihara T, Kohno K, Ushio S, Iwaki K, Ikeda M, Kurimoto M. Tryptanthrin inhibits nitric oxide and prostaglandin E₂ synthesis by murine macrophages. Eur J Pharmacol 2000; 407: 197-204
• 7 Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Protective effects of nimesulide (COX inhibitor), AKBA (5-LOX inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find Exp Clin Pharmacol 2005; 27: 465-470
• 8 Dokmeci D. Ibuprofen and Alzheimerʼs disease. Folia Med (Plovdiv) 2004; 46: 5-10
• 9 Guidance for Industry: Bioanalytical Method Validation. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research, May 2001. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed 17.07.2015
• 10 Guideline on bioanalytical method validation. European Medicines Agency (EMEA/CHMP/EWP/192217/2009). London, 21 July 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf Accessed 16.07.2015
• 11 Oufir M, Sampath C, Butterweck V, Hamburger M. Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 902: 27-34
• 12 Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007; 2: 2111-2119
• 13 Wegener J, Abrams D, Willenbrink W, Galla HJ, Janshoff A. Automated multi-well device to measure transepithelial electrical resistances under physiological conditions. Biotechniques 2004; 37: 590
• 14 Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005; 25: 59-127
• 15 Gaillard PJ, de Boer AG. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000; 12: 95-102
• 16 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26
• 17 Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45: 2615-2623
• 18 van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151-165
• 19 Culot M, Lundquist S, Vanuxeem D, Nion S, Landry C, Delplace Y, Dehouck MP, Berezowski V, Fenart L, Cecchelli R. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol In Vitro 2008; 22: 799-811
• 20 Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009; 54: 253-263
• 21 Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 2013; 10: 33
• 22 Mohn T, Potterat O, Hamburger M. Quantification of active principles and pigments in leaf extracts of Isatis tinctoria by HPLC/UV/MS. Planta Med 2007; 73: 151-156
• 23 Rüster GU, Hoffmann B, Hamburger M. Inhibitory activity of indolin-2-one derivatives on compound 48/80-induced histamine release from mast cells. Pharmazie 2004; 59: 236-237
• 24 Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010; 99: 306-314
• 25 Jähne EA, Eigenmann DE, Culot M, Cecchelli R, Walter FR, Deli MA, Tremmel R, Fricker G, Smiesko M, Hamburger M, Oufir M. Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. J Pharm Biomed Anal 2014; 98: 235-246
• 26 Dehouck MP, Méresse S, Delorme P, Fruchart JC, Cecchelli R. An easier, reproducible, and mass‐production method to study the blood-brain barrier in vitro . J Neurochem 1990; 54: 1798-1801
• 27 Booher J, Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 1972; 2: 97-105
• 28 Boveri M, Berezowski V, Price A, Slupek S, Lenfant AM, Benaud C, Hartung T, Cecchelli R, Prieto P, Dehouck MP. Induction of blood‐brain barrier properties in cultured brain capillary endothelial cells: Comparison between primary glial cells and C6 cell line. Glia 2005; 51: 187-198
• 29 Veszelka S, Tóth AE, Walter FR, Datki Z, Mózes E, Fülöp L, Bozsó Z, Hellinger E, Vastag M, Orsolits B, Környei Z, Penke B, Deli MA. Docosahexaenoic acid reduces amyloid-β induced toxicity in cells of the neurovascular Unit. J Alzheimers Dis 2013; 36: 487-501
• 30 Walter FR, Veszelka S, Pásztói M, Péterfi ZA, Tóth A, Rákhely G, Cervenak L, Ábrahám CS, Deli MA. Tesmilifene modifies brain endothelial functions and opens the blood-brain/blood-glioma barrier. J Neurochem 2015; 134: 1040-1054
• 31 Youdim KA, Avdeef A, Abbott NJ. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 2003; 8: 997-1003
• 32 Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-628
• 33 Hellinger É, Veszelka S, Tóth AE, Walter F, Kittel Á, Bakk ML, Tihanyi K, Háda V, Nakagawa S, Duy TD, Niwa M, Deli MA, Vastag M. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 2012; 82: 340-351